https://commons.ru.ac.za/vital/access/manager/Index en-us 5 https://commons.ru.ac.za/vital/access/manager/Repository/vital:26680 Wed 12 May 2021 23:40:48 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:26591 Wed 12 May 2021 20:00:07 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:26592 Wed 12 May 2021 19:00:54 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28598 Wed 12 May 2021 18:27:23 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:20376 Wed 12 May 2021 17:27:22 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28597 Wed 12 May 2021 17:17:15 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28554 Wed 12 May 2021 16:45:43 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28542 Wed 12 May 2021 16:09:18 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:20381 Thu 29 Sep 2022 14:28:44 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:26599 0.999 were obtained for each assessment of linearity and FTC, TNF and EFV are linear in the range 0.4-40 μg/ml, 0.6-60 μg/ml and 1.2-120 μg/ml. The equation of the best-fit least squares regression lines for FTC, TNF and EFV were y = 0.0191x+0.0007, y = 0.0163x+0.0116 and y = 0.01x+0.016, respectively. The method is accurate as the y-intercept was < 2% of the detector response for all ARV, and the method is precise in terms of intra- and inter-assay precision as all % RSD < 2%. The stability-indicating nature of the method was demonstrated under acidic, alkaline and oxidative stress in addition to UV exposure and elevated temperatures, and the individual chromatograms were overlaid using Empower® 3 Software to establish whether there was interference with the peaks of interest. The forced degradation studies demonstrated the selectivity of the method for the ARV compounds. The method was applied to assay and in vitro dissolution studies of commercially available tablets. The amount of each active ingredient released from Atripla® was determined and compared to the amount of each drug released from Aspen Efavirenz® and Truvada® (a combination of FTC and TNF). The percent FTC released from Atripla® and Truvada® was similar based on the acceptance criteria for immediate-release BCS class 1 compounds. Statistical analysis was undertaken to compare the dissolution profiles of FTC, TNF and EFV. The percent of these compounds released in these studies indicate that bioequivalence testing would be required to declare these products interchangeable. The validated RP-HPLC and in vitro dissolution test method are suitable for routine quality control testing of solid oral dosage forms containing EFV, FTC and TNF, and as the dissolution method can discriminate between different formulations of the same molecule, these tools can also be used for analysis during formulation development studies. The method is not suitable for the analysis of the ARV plasma due to lack of sensitivity and an inability to quantitate the compounds at the required concentration levels. The use of HPLC with mass spectroscopy for quantitation would enhance the sensitivity of the method and may eliminate the quantitation of the molecules in the presence of interference that was observed when using UV detection. Fixed dose combination tablets are convenient for patient therapy and it is likely that in the future more molecules will be formulated into such dosage forms. However formulations such as these can pose significant difficulties when developing and using analytical methods for the quantitation of all compounds in the dosage form at the same time, in particular when the compounds have vastly different physico-chemical properties that impact the quality of a separation and therefore the analysis. Therefore when embarking on the development of FDC product cognisance of the difficulties of developing single methods for the analyses is required and approaches to overcome these difficulties should be considered.]]> Thu 13 May 2021 08:54:37 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:26587 Thu 13 May 2021 08:16:57 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:20393 Thu 13 May 2021 06:58:53 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:29391 Thu 13 May 2021 06:19:50 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:26704 Thu 13 May 2021 04:45:06 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28592 Thu 13 May 2021 03:43:13 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28599 Thu 13 May 2021 03:29:39 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28555 Thu 13 May 2021 01:46:27 SAST ]]> https://commons.ru.ac.za/vital/access/manager/Repository/vital:28559 Thu 13 May 2021 00:11:47 SAST ]]>